Residual systemic inflammatory burden is a major determinant of myocardial recovery and late cardiovascular outcome in Takotsubo patients - 09/01/21
, B. Marchandot 1, K. Matsushita 1, C. Sato 1, C. Dagrenat 2, S. Greciano 3, F. De Poli 2, P. Leddet 2, A. Carmona 1, C. Jimenez 1, J. Heger 1, A. Reydel 1, P. Ohlmann 1, L. Jesel 1, O. Morel 1
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Résumé |
Background |
Recent insights have emphasized the importance of myocardial and systemic inflammation in Takotsubo syndrome (TTS).
Purpose |
In a large registry of unselected patients, we sought to evaluate whether residual high inflammatory response (RHIR) could impact cardiovascular outcome after TTS.
Methods |
Patients with TTS were retrospectively included between 2008 and 2018 in three general hospitals. 385 patients with TTS were split into three subgroups, according to tertiles of C-reactive protein (CRP) levels at discharge (CRP<5.2mg/l, CRP range 5.2 to 19mg/l, and CRP>19mg/l). The primary endpoint was the impact of RHIR, defined as CRP>19mg/l at discharge, on cardiac death or hospitalization for heart failure.
Results |
Follow-up was obtained in 382 patients (99%) after a median of 747 days. RHIR patients were more likely to have a history of cancer or a physical trigger. Left ventricular ejection fraction (LVEF) at admission and at discharge was comparable between groups. By contrast, RHIR was associated with lower LVEF at follow-up (61.7 vs. 60.7 vs. 57.9%; P=0.004) and increased cardiac late mortality (0% vs. 0% vs. 10%; P=0.001). By multivariate Cox regression analysis, RHIR was an independent predictor of cardiac death or hospitalization for heart failure (hazard ratio: 1.97; 95% confidence interval: 1.11 to 3.49; P=0.02).
Conclusions |
RHIR was associated with impaired LVEF recovery and was evidenced as an independent factor of cardiovascular events. All together these findings underline RHIR patients as a high-risk subgroup, to target in future clinical trials with specific therapies to attenuate RHIR.
Le texte complet de cet article est disponible en PDF.Plan
Vol 13 - N° 1
P. 152-153 - janvier 2021 Retour au numéro
Article précédent
- Incidence, timing, predictors, and impact of sustained ventricular arrythmias complicating ST-segment elevation myocardial infarction
- H. Bourenane, V. Auffret, R. Martins
- Prospective study in young women presenting acute MYOCARDIAL infarction in France: Clinical, morphological and biological descriptive analysis: WAMIF Study
- S. Manzo-Silberman, E. Vautrin, A. Bellemain-Appaix, F. Couturaud, A. Gompel, L. Drouet, S. Marliere, C. Bal Dit Sollier, S. Uhry, H. Eltchaninoff, T. Bergot, P. Motreff, Y. Cottin, C. Mounier-Vehier, M. Gilard
Bienvenue sur EM-consulte, la référence des professionnels de santé.